Recombinant Anti-Mullerian Hormone
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Undetermined
-
Intended Duration:
- Undetermined
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): Oviva Therapeutics, Massachussetts General Hospital
Details
- API: AMH
- Target: Mullerian Development
-
Mechanism of Action:
- Other
- Inactive Materials: Undetermined
- Regimen: Undetermined
- MPT: Not Potential MPT
Product Status
No evidence of human development after 2017
History
Largely evaluated for veterinary applications, with limited evidence for human use